Made to do more.

Cost Effective

cost effective
  • Infasurf vial sizes enable clinicians to treat 73% of patients with a single vial.
  • Only 37% of patients can be treated with a single vial of Curosurf.
  • An independent study found the average cost per patient was 38% less with Infasurf compared to Curosurf.4
  • Two vial sizes directly related to dose volumes minimize waste

Infasurf® (calfactant) – Each Dose1

Infasurf Each Dose

Curosurf® (poractant alfa) – Initial Dose2

Curosurf Initial Dose

Disclaimer:

There are no prospective, randomized clinical trials comparing Infasurf and Curosurf with respect to safety or efficacy.

References:

1. Infasurf® (calfactant) Intratracheal Suspension Prescribing Information, ONY Biotech, March 2018. 2. Curosurf® (poractant alfa) Intratracheal Suspension Prescribing Information, Chiesi USA Inc. December 2014. 3. Trembath A, Hornik CP, Clark R, et al. Comparative effectiveness of surfactant preparations in premature infants. J Pediatr. 2013;163(4):955-960. 4. Zayek MM, Eyal FG, Smith RC. Comparison of the pharmacoeconomics of calfactant and poractant alfa in surfactant replacement therapy. JPPT. 2018;23(2):146-151.